Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1Phase 1/2 1

Status

Recruiting 6Not yet recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 3Breast 3

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Fallopian Tube Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Biosimilar Pharmaceuticals × Clear all
NCT03564340 2026-05-08

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
890 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07220135 2026-05-06

NeoTHERa

University of Kansas Medical Center

Phase 2 Recruiting
100 enrolled
Breast

Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
50 enrolled
Breast

Breast Neoplasms

NCT06292286 2025-06-11

SCENIC

The University of Hong Kong

Phase NA Recruiting
18 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡